

I. Appendix

A. Model structure and parameters




Figure: Model structure

Table: Model parameters and assumptions

Parameter	Description	Type	Source data
GPT015	Annual proportion of the general population aged 0-14 transitioning to age group 15-49	Calculated, dynamic	World Population Prospects 2017 ¹²
GP_AGE	Annual proportion of 15-49 year olds in the general population transitioning to 50+ age group	Calculated, dynamic	World Population Prospects 2017 ¹²
GSA	General population annual risk of type III FGM in 0-14 age group	Calculated, static	Demographic and Health Survey (DHS) or Multiple Indicator Cluster Survey (MICS) data ^{109,110,119–128,111,129–136,112–118}
GMA	General population annual risk of type I/II FGM in 0-14 age group	Calculated, static	Demographic and Health Survey (DHS) or Multiple Indicator Cluster Survey (MICS) data ^{109,110,119–128,111,129–}

			136,112–118
SevFGMTo15/ ModFGMTo15	Annual proportion of girls with type III/type I or II FGM in 0-14 year age group transitioning to 15-49 age group	Calculated	World Population Prospects 2017 ¹²
SFGM_AGE/ MFGM_AGE	Annual proportion of 15-49 year old women with type III/type I or II FGM transitioning to 50+ age group	Calculated, dynamic	World Population Prospects 2017 ¹²
SDE	Type III FGM deinfibulation rate	Static	[Not implemented]
FER	Annual estimated General Fertility Rate	Database, dynamic	World Population Prospects 2017 ¹²
MRC	Background mortality rate in children 0-14 years	Calculated, dynamic	WHO Global Health Observatory ¹³⁷
MRA	Background mortality rate in adults 15-49 years	Calculated, dynamic	WHO Global Health Observatory ¹³⁷
MRE	Background mortality rate in later life, 50+ years	Calculated, dynamic	WHO Global Health Observatory ¹³⁷
IntEff	Intervention effectiveness factor as proportion of baseline (0 = 100% effective; 1 = 0% effective in reducing incidence)	Static	Assumption

B. Transition probabilities

Table: Transition probabilities

	GP014	GP15Plus	SevereAcute	ModerateAcute	SeverePostAcute	ModeratePostAcute	SevereFGMPre	ModerateFGMPre	SevereFGMRep	ModerateFGMRep	DeinfibPre	DeinfibRep	AlIFGM50Plus	GP50Plus	Death
GP014	C	GPTo15	IntEff*GSA	IntEff*GMA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	MRC
GP15Plus	0.00	C	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	GP_AGE	MRA
SevereAcute	0.00	0.00	0.00	0.00	C	0.00	SevFGMTto15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	MRC
SeverePostAcute	0.00	0.00	0.00	0.00	C	0.00	SevFGMTto15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	MRC
ModerateAcute	0.00	0.00	0.00	0.00	0.00	C	0.00	ModFGMTto15	0.00	0.00	0.00	0.00	0.00	0.00	MRC
ModeratePostAcute	0.00	0.00	0.00	0.00	0.00	C	0.00	ModFGMTto15	0.00	0.00	0.00	0.00	0.00	0.00	MRC
SevereFGMPre	0.00	0.00	0.00	0.00	0.00	0.00	C	0.00	FER	0.00	0.00	0.00	SFGM_AGE	0.00	MRA
ModerateFGMPre	0.00	0.00	0.00	0.00	0.00	0.00	0.00	C	0.00	FER	0.00	0.00	MFGM_AGE	0.00	MRA
SevereFGMRep	0.00	0.00	0.00	0.00	0.00	0.00	C	0.00	0.00	0.00	SDE	0.00	0.00	0.00	MRA
ModerateFGMRep	0.00	0.00	0.00	0.00	0.00	0.00	0.00	C	0.00	0.00	0.00	0.00	0.00	0.00	MRA
DeinfibPre	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	C	FER	SFGM_AGE	0.00	MRA
DeinfibRep	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	C	0.00	0.00	0.00	MRA
AlIFGM50Plus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	C	0.00	MRE
GP50Plus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	C	MRE
Death	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	C

C: Complement (the number which makes the row sum equal to 1.0, given all other transition values); *GPTo15*: Annual proportion of the general population 0-14 age group transitioning to 15+ (proportion of 14-year olds); *IntEff*: Intervention Effectiveness, expressed as factor of current incidence rate (1.0 = business as usual, 0.0 = elimination); *GSA*: General population to severe FGM (acute); *GMA*: General population to moderate FGM (acute); *GP_AGE*: Annual proportion of 15-49 year olds in the general population transitioning to 50+ (proportion of 49-year olds); *SevFGMTto15/ModFGMTto15*: Annual proportion of the severe/moderate FGM affected population 0-14 year age group transitioning to 15+ (proportion of 14-year olds); *FER*: Annual fertility; *SFGM_AGE/MFGM_AGE*: Annual proportion of 15-49 year old severe/moderate FGM population transitioning to 50+; *SDE*: Severe FGM deinfibulation rate; *AGE*: Annual proportion of 15-49 age group transitioning to 50+; *MRC*: Mortality Rate in children (0-14 years); *MRA*: Mortality Rate in Adults 15-49 years); *MRE*: Mortality Rate in Elderly (50+)*

C. Calculation of incidence of FGM

The prevalence of FGM was taken from the most recent Demographic and Health Survey (DHS) or Multiple Indicator Cluster Survey (MICS) data. Prevalence data denotes the prevalence of FGM, and breakdown by type, in the 15-49 age group of the surveyed population. The annual incidence in the 0-14 year age group was estimated by considering the prevalence figure a 15-year cumulative risk, and rescaling to a 1-year risk. This approach is based on the assumptions that all FGM occurs in the 0-14 age group, and that FGM results in a lifelong condition. To illustrate, consider a hypothetical cohort of 100 newborn females over a time horizon of 15 years, and assume the prevalence of FGM in the 15+ population is 10%. The following table illustrates the development of the cohort over time, using a 10% 15-year risk annualized to a 1-year risk of 0.70%:

Years of age	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	...
No FGM	0	99.3	98.6	97.9	97.2	96.5	95.9	95.2	94.5	93.9	93.2	92.6	91.9	91.3	90.6	90.0	90.0	...
FGM performed in year*	0	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.0	...
Total FGM	0	0.7	1.4	2.1	2.8	3.5	4.1	4.8	5.5	6.1	6.8	7.4	8.1	8.7	9.4	10.0	10.0	...

* 0.7% of last years “No FGM”

The risk of new cases of FGM becomes zero at year 15, and consequently the population reaches a steady state with a prevalence of 10%, which was the starting point.

D. Calculation of background mortality rate

Background mortality by age group is sourced from the WHO Global Health Observatory (GHO) indicator **LIFE_0000000030**¹³⁸. Five-year mortality rates for the five-year age buckets reported by the GHO were converted to one-year mortality rates in the 0-14, 15-49 and 50-84 age groups by first enumerating the number of deaths experienced in a hypothetical cohort of 100 individuals during the course of 15, 35 and 35 years, respectively, and then rescaling that probability of death to a one-year risk.

As an example, consider Benin which has age-specific mortality rates of 0.060, 0.037, 0.014 and 0.008 for the age groups <1, 1-4, 5-9 and 10-14 years, respectively. This results in a total of 11.46 deaths over the period of 15 years. Rescaling this 15-year risk of 0.1146 to a 1-year risk gives 0.008081062.

Country	country_ISO3	AGELT1	AGE1-4	AGE5-9	AGE10-14
Benin	BEN	0.06	0.037	0.014	0.008
	Alive	100	94	90.522	89.254692
	Dead	6	3.478	1.267308	0.7140375
	Alive end of period	94	90.522	89.25469	88.540654
	Cohort size (control)	100	100	100	100
	Total deaths:				11.459346

To verify, we can apply the calculated 1-year risk to a hypothetical cohort over 15 years, as shown below. It can be seen that the total number of deaths after 15 years is identical to the number of deaths calculated using the original GHO data.

Year	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Alive	100	99.191894	98.39032	97.59522	96.80655	96.02425	95.24827	94.47856	93.71507	92.95776	92.20656	91.46143	90.72233	89.98919	89.26199
Dead	0.8081062	0.8015758	0.795098	0.788673	0.7823	0.775978	0.769707	0.763487	0.757317	0.751197	0.7451269	0.739106	0.733133	0.727208	0.721332
Alive end of period	99.1918938	98.390318	97.59522	96.806547	96.02425	95.24827	94.47856	93.71507	92.95776	92.20656	91.461433	90.72233	89.98919	89.26199	88.54065
Cohort size (control)	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
Cumulative deaths:	0.8081062	1.609682	2.40478	3.1934533	3.975753	4.751731	5.521438	6.284925	7.042243	7.79344	8.5385669	9.277672	10.01081	10.73801	11.45935

E. Unit costs for clinical interventions from OneHealth Tool

OneHealth Tool intervention number(s)	Consultations		Commodities							
	Average inpatient days	Average outpatient consultations	Medicines	% of cases receiving	Unit cost (per tab/cap, vial, mL, g)	Source	Units required	Total cost (2015 US\$)	Total cost weighted (2015 US\$)	Total weighted cost 2018 US\$
46: Urinary Tract Infection (UTI)	0.5	0.5	Amoxicillin, 500mg tablet 3x a day for 3 days (\$0.30)	100%	0.03	http://mshpriceguide.org/en/single-drug-information/?DMFId=42&searchYear=2015	9	\$ 0.27	\$ 0.27	
Total									\$ 0.27	\$ 0.29
28: Obstructed Labor	7	0								
-- Spinal anaesthesia			Sodium lactate (Ringer) + set, 500ml, 2x	50%	0.00	http://mshpriceguide.org/en/single-drug-information/?DMFId=726&searchYear=2015	1000	\$ 1.00	\$ 0.50	
			Lidocaine HCl, 2ml ampoule, 1x	50%	0.03	http://mshpriceguide.org/en/single-drug-information/?DMFId=470&searchYear=2015	2	\$ 0.06	\$ 0.03	

	<i>Epinephrine injection, 1mg (as hydrochloride) in 1ml ampoule, 1x</i>	25%	0.19	http://mshpriceguide.org/en/single-drug-information/?DMFId=298&searchYear=2015	1	\$ 0.19	\$ 0.05
	<i>Epinephrine injection, 1mg (as hydrochloride) in 1ml ampoule, 1x</i>	10%	0.19	http://mshpriceguide.org/en/single-drug-information/?DMFId=298&searchYear=2015	1	\$ 0.19	\$ 0.02
-- General anaesthesia	<i>Ketamine injection 50mg (as hydrochloride)/ml in 10ml vial, 1x</i>	50%	0.15	http://mshpriceguide.org/en/single-drug-information/?DMFId=454&searchYear=2015	10	\$ 1.55	\$ 0.77
	<i>Sodium lactate (Ringer) + set, 500mL, x2</i>	50%	0.00	http://mshpriceguide.org/en/single-drug-information/?DMFId=726&searchYear=2015	1000	\$ 1.00	\$ 0.50
	<i>Atropine, injection, 1mg (sulfate) in 1mL ampoule</i>	50%	0.12	http://mshpriceguide.org/en/single-drug-information/?DMFId=78&searchYear=2015	1	\$ 0.12	\$ 0.06
-- Prophylactic antibiotics	<i>Ampicillin, powder for injection, 500mg, vial, 4x</i>	100%	0.37	http://mshpriceguide.org/en/single-drug-	4	\$ 1.48	\$ 1.48

				information/?DMFId=53&searchYear=2015			
-- Procedure	<i>Povidone iodine, solution, 10%, 1x (1bott(250ml))</i>	100%	0.01	http://mshpriceguide.org/en/singledrug-information/?DMFId=678&searchYear=2015	250	\$ 1.88	\$ 1.88
-- If signs of infection	<i>Sodium chloride injectable solution, 0.9% isotonic, 500ml, 8x</i>	25%	0.00	http://mshpriceguide.org/en/singledrug-information/?DMFId=724&searchYear=2015	4000	\$ 4.40	\$ 1.10
	<i>Ampicillin, powder for injection, 500mg, vial, 64x</i>	25%	0.37	http://mshpriceguide.org/en/singledrug-information/?DMFId=53&searchYear=2015	64	\$ 23.65	\$ 5.91
	<i>Getamycin injection, 40mg (as sulfate)/ml in 2-ml vial, 28x</i>	25%	0.06	http://mshpriceguide.org/en/singledrug-information/?DMFId=370&searchYear=2015	56	\$ 3.45	\$ 0.86
	<i>Metronidazole, injection, 500 mg in 100 ml vial, 12x</i>	25%	0.00	http://mshpriceguide.org/en/singledrug-information/?DMFId=523&searchYear=2015	1200	\$ 4.68	\$ 1.17

-- After delivery			<i>Pethidine, HCl 50 mg/ml, 2 ml, 1x</i>	100%	0.25	http://mshpriceguide.org/en/singledrug-information/?DMFId=617&searchYear=2015	2	\$ 0.50	\$ 0.50
			<i>Sodium lactate (Ringer) + set, 500ml, 2x</i>	100%	0.00	http://mshpriceguide.org/en/singledrug-information/?DMFId=726&searchYear=2015	1000	\$ 1.00	\$ 1.00
			<i>Oxytocin, injection, 10 IU in 1 ml ampoule, 2x</i>	100%	0.17	http://mshpriceguide.org/en/singledrug-information/?DMFId=580&searchYear=2015	2	\$ 0.33	\$ 0.33
			<i>Paracetamol, tablet, 500 mg, 12x</i>	100%	0.01	http://mshpriceguide.org/en/singledrug-information/?DMFId=592&searchYear=2015	12	\$ 0.07	\$ 0.07
Total								\$ 16.24	\$ 17.63
OHT 28: Obstructed labour	1	0							
			<i>Povidone Iodine solution (10%), 1x (1bott(250ml))</i>	100%	0.01	http://mshpriceguide.org/en/singledrug-information/?D	250	\$ 1.88	\$ 1.88

				MFIId=678&searchYear=2015			
	<i>Oxytoxin injection 10 IU in 1ml ampoule, 1x</i>	100%	0.17	http://mshpriceguide.org/en/single-drug-information/?D MFIId=580&searchYear=2015	1	\$ 0.17	\$ 0.17
	Paracetamol 500mg, 12x	100%	0.01	http://mshpriceguide.org/en/single-drug-information/?D MFIId=592&searchYear=2015	12	\$ 0.07	\$ 0.07
-- Episiotomy or tears	<i>Lidocaine HCl, 2ml ampoule, 1x</i>	100%	0.03	http://mshpriceguide.org/en/single-drug-information/?D MFIId=470&searchYear=2015	2	\$ 0.06	\$ 0.06
-- After delivery	<i>Pethidine, HCl 50mg/ml, 2ml, 1x</i>	50%	0.25	http://mshpriceguide.org/en/single-drug-information/?D MFIId=617&searchYear=2015	2	\$ 0.50	\$ 0.25
-- Other	<i>Paracetamol, tablet, 500 mg, 12x</i>	100%	0.01	http://mshpriceguide.org/en/single-drug-information/?D MFIId=592&searchYear=2015	12	\$ 0.07	\$ 0.07
Total						\$	\$ 2.71

								2.49	
OHT 28: Obstructed labour	0	0	<i>Lidocaine HCl, 2ml ampoule, 1x</i>	100%	0.03	http://mshpriceguide.org/en/single-drug-information/?DMFId=470&searchYear=2015	2	\$ 0.06	\$ 0.06
Total								\$ -	\$ 0.06
									\$ 0.07
OHT 30: Newborn resuscitation (clinic-based deliveries)	0	0	Bag and Mask (\$90) divided by average caseload of midwife (200 births per year)	100%	90.00		0	\$ 0.45	\$ 0.45
Total									\$ 0.45
									\$ 0.49
OHT 172: Basic psychosocial treatment for anxiety disorders (mild cases)	0	2	<i>There are no drugs or supplies for this according to OHT</i>					\$ -	
OHT 173: Basic psychosocial treatment and anti-depressant medication for anxiety disorders (moderate-	0.28	2	<i>Fluoxetine 20mg tab, 180 tabs (\$0.0083/tab-cap)</i>	75%	0.01	http://mshpriceguide.org/en/single-drug-information/?DMFId=357&searchYear=2015	180	\$ 1.85	\$ 1.39

severe cases)									
			<i>Amitriptyline 50mg tab, 270 tabs (\$0.0330/tab-cap)</i>	25%	0.03	http://mshpriceguide.org/en/single-drug-information/?DMFId=1278&searchYear=2015	270	\$ 8.91	\$ 2.23
Total								\$ 3.62	\$ 3.93
OHT 175: Intervention 175: Basic psychosocial treatment for mild depression	2		<i>There are no drugs or supplies for this according to OHT</i>						
OHT 176: Depression - Basic psychosocial treatment and anti-depressant medication of first episode moderate-severe cases	0.28	2	Fluoxetine 20mg tab, 180 tabs	75%	0.01	http://mshpriceguide.org/en/single-drug-information/?DMFId=357&searchYear=2015	180	\$ 1.85	\$ 1.39
			Amitriptyline 50mg tab, 270 tabs	25%	0.03	http://mshpriceguide.org/en/single-drug-	270	\$ 8.91	\$ 2.23

	information/?D MFId=1278&se archYear=2015		
Total		\$ <u>3.62</u>	\$ <u>3.93</u>

F. Unit costs for clinical interventions from targeted literature reviews

Introduction

This section presents the results of the pragmatic/targeted literature review to identify sources of costing data based on the list of FGM-related interventions provided by the technical counterpart.

Background

To determine the direct economic burden of specific health outcomes related to FGM, we need to understand how each outcome would be managed in a typical LMIC healthcare system. This includes an appreciation of which outcomes would be managed in formal care, and which outcomes would be not managed at all, or in informal care/through self-care.

Search Strategy

We searched 2 bibliographical electronic results for indexed articles:

- ISI Web of Science (WoS)
- Grey literature (internet via Google)

The searches were performed in October to November 2019. A single screener was be used.

Search Results

General remarks

From the results of the literature search, FGM appears to be under-studied. We were unable to find much economic evidence specifically for FGM. For this reason, we widened the searches. A large number of the results were focused on areas outside of the scope of this search. There were numerous results for urinary tract infections, chlamydia, cancers, spinal cord injuries. For this reason, we explicitly omitted terms in searches.

Search terms

The search in databases included titles, abstracts and keywords, without any restriction regarding time period.

The same key words were used when searching the Grey literature.

Where there were no search term results returned, some search terms were dropped and a second search carried out.

Searches are labelled "Search X" when there are sources returned. This corresponds with folder names in corresponding files with all search term results in .ris and plain text formats.

Wound and ulcer management

TS=(fgm* OR "female genital mutilation") AND TS=(wound* OR management* OR ulcer* OR treatment*) AND TS=(immediate* OR acute*) AND TS=cost*

Result: No results found

Search 1:

TS=(fgm* OR "female genital mutilation") AND TS=(wound* OR management* OR ulcer* OR treatment*) AND TS=cost*

Result: 46 found; 2 screened for review; no values found.

Search 2:

TS=(genital* OR urolog* OR fgm*) AND TS=(wound* OR management* OR ulcer* OR treatment*)
AND TS=(immediate* OR acute*) AND TS=cost* NOT TS=(renal* OR prostate* OR cancer* OR heart* OR
coronary* OR stone* OR diabetes* or transplant*)

Result: 370 found; none passed screening

(Clitoral) Neuroma management/treatment

Search 3:

TS=(fgm* OR "female genital mutilation") AND TS=(clitoral* OR neuroma*) AND
TS=(immediate* OR acute*) AND TS=cost*

Result: No results found

TS=(fgm* OR "female genital mutilation") AND TS=(clitoral* OR neuroma*) AND TS=cost*

Result: No results found

Search 4:

TS=(clitoral* OR neuroma*) AND TS=(immediate* OR acute*) AND TS=cost*

Result: 14 results found

Keloid management/treatment

TS=(fgm* OR "female genital mutilation") AND TS=(keloids* OR scar*) AND
TS=(immediate* OR acute*) AND TS=cost*

Result: No results found

TS=(fgm* OR "female genital mutilation") AND TS=(keloids* OR scar*) AND TS=cost*

Result: 2 found; none passed screening

Post-traumatic stress syndrome (PTSD)

TS=(fgm* OR "female genital mutilation") AND TS=('Post-traumatic stress' OR PTSD*)
AND TS=(immediate* OR acute*) AND TS=cost*

Result: No results found

TS=(fgm* OR "female genital mutilation") AND TS=('Post-traumatic stress' OR PTSD*)
AND TS=cost*

Result: No results found

More general searches

Search 5:

TS=(fgm* OR "female genital mutilation") AND TS=cost*

Result: 36 passed screening; no values found.

Search 6:

TS=(fgm* OR "female genital mutilation") AND TS=(wound* OR management* OR ulcer* OR treatment*)

Result: 34 passed screening; no values found.

Grey literature

All terms above we searched using UK Google search engine.

Result: 12 documents were found that were potentially of interest. 4 were screened to be accepted for closer reading.

Results from these papers are given in the file *grey_lit_results_data.xlsx*.

In particular, Hex (2016) has estimates of PTSD, excessive bleeding and wound healing. Guest (2016) gives resource use by wound type.

These references were:

- Health economic burden that different wound types impose on the UK's National Health Service, Julian F Guest, Nadia Ayoub, Tracey McIlwraith, Ijeoma Uchegbu, Alyson Gerrish, Diana Weidlich, Kathryn Vowden & Peter Vowden, International Wound Journal ISSN 1742-4801
- Estimating the obstetric costs of female genital mutilation in six African countries, Taghreed Adam, Heli Bathija, David Bishai, Yung-Ting Bonnenfant, Manal Darwish, Dale Huntington & Elise Johansen for the FGM Cost Study Group of the World Health Organization, Bull World Health Organ 2010;88:281–288 | doi:10.2471/BLT.09.064808
- Estimating the costs of Female Genital Mutilation services to the NHS, Nick Hex, Jo Hanlon, Dianne Wright, Veronica Dale, Professor Karen Bloor, The Kings Fund, University of York Report, May 2016, <https://www.york.ac.uk/media/healthsciences/images/research/prepare/reportsandtheircoverimages/EstimatingCostsOfFGMServices.pdf>
- Female genital mutilation/cutting in Africa, Akin-Tunde A. Odukogbe, Bosede B. Afolabi, Oluwasomidoyin O. Bello, Ayodeji S. Adeyanju, Transl Androl Urol 2017;6(2):138-148

G. Sensitivity analyses

Parameter	Description	Range applied in sensitivity analysis
GSA	Annual incidence of type III FGM in 0-14 year olds	[0.5*country point estimate; 2*country point estimate]
GMA	Annual incidence of moderate FGM in 0-14 year olds	[0.5*country point estimate; 2*country point estimate]
SDE	Deinfibulation rate in type III FGM	[0.5*country point estimate; 2*country point estimate]
AnnualInflow	Annual number of births	[0.5*country point estimate; 1.5*country point estimate]
MRC	Background mortality rate in children	[0.5*country point estimate; 2*country point estimate]
MRA	Background mortality rate in adults	[0.5*country point estimate; 2*country point estimate]
MRE	Background mortality rate in elderly	[0.5*country point estimate; 2*country point estimate]
acute_cost_value_acute	Childhood total annual costs of recurring acute complications	[0.25*country point estimate; 4*country point estimate]
acute_cost_value_infection	Childhood total annual costs of recurring infections	[0.25*country point estimate; 4*country point estimate]
acute_cost_value_scarring	Childhood total annual costs of recurring scarring	[0.25*country point estimate; 4*country point estimate]
acute_cost_value_obstetric	Childhood total recurring annual costs in obstetrics	[0.25*country point estimate; 4*country point estimate]
onetime_acute_cost_value_acute	Childhood total annual costs of one-time acute complications	[0.25*country point estimate; 4*country point estimate]
onetime_acute_cost_value_infection	Childhood total annual costs of one-time infections	[0.25*country point estimate; 4*country point estimate]
onetime_acute_cost_value_scarring	Childhood total annual costs of scarring (one-time)	[0.25*country point estimate; 4*country point estimate]
onetime_acute_cost_value_obstetric	Childhood total annual one-time costs in obstetrics	[0.25*country point estimate; 4*country point estimate]
adultnonrep_cost_value_acute	Adulthood total annual costs of recurring acute complications	[0.25*country point estimate; 4*country point estimate]
adultnonrep_cost_value_infection	Adulthood total annual costs of recurring infections	[0.25*country point estimate; 4*country point estimate]
adultnonrep_cost_value_scarring	Adulthood total annual costs of recurring scarring	[0.25*country point estimate; 4*country point estimate]
adultnonrep_cost_value_obstetric	Adulthood total recurring annual costs in obstetrics	[0.25*country point estimate; 4*country point estimate]

rep_cost_value_acute	Adulthood total annual costs of recurring acute complications during reproduction	[0.25*country point estimate; 4*country point estimate]
rep_cost_value_infection	Adulthood total annual costs of recurring infections during reproduction	[0.25*country point estimate; 4*country point estimate]
rep_cost_value_scarring	Adulthood total annual costs of recurring scarring during reproduction	[0.25*country point estimate; 4*country point estimate]
rep_cost_value_obstetric	Adulthood total recurring annual costs in obstetrics during reproduction	[0.25*country point estimate; 4*country point estimate]
laterlife_cost_value_acute	Later life total annual costs of recurring acute complications	[0.25*country point estimate; 4*country point estimate]
laterlife_cost_value_infection	Later life total annual costs of recurring infections	[0.25*country point estimate; 4*country point estimate]
laterlife_cost_value_scarring	Later life total annual costs of recurring scarring	[0.25*country point estimate; 4*country point estimate]
laterlife_cost_value_obstetric	Later life total recurring annual costs in obstetrics	[0.25*country point estimate; 4*country point estimate]

H. Data download links

Data download links

Life tables

Life tables (background mortality)	Example API call: http://apps.who.int/gho/athena/api/GHO/LIFE_0000000030.csv?filter=COUNTRY:*;REGION:AFR;YEAR:2016	The WHO server is unable to handle download of data for all years. There is no data for 2018 or 2017. Only the most recent year is needed.
---------------------------------------	--	--

I. Prevalence sources

Country	Data source	Year of survey	Adult prevalence (% 15-49yrs)
Benin	DHS	2011-2012	7.3
Burkina Faso	DHS	2010	75.8
Cameroon	MICS	2014	1.0
Central African Republic (The)	MICS	2010	24
Chad	DHS	2014-2015	38.4
Côte d'Ivoire	DHS	2011-2012	38.2
Djibouti	MICS	2006	93.0
Egypt	HIS	2015	87.2
Eritrea	DHS	2002	88.7
Ethiopia	DHS	2016	65.2
Gambia (The)	DHS	2013	74.9
Ghana	MICS	2011	3.8
Guinea	DHS	2018	94.5
Guinea-Bissau	MICS	2014	45.0
Indonesia	RISKESDAS	2013	49.0
Iraq	MICS	2018	7.4
Kenya	DHS	2014	21.0
Liberia	DHS	2013	44.0
Mali	DHS	2018	88.6
Mauritania	MICS	2015	67.0

Niger (The)	DHS/MICS	2012	2.0
Nigeria	DHS	2018	19.5
Senegal	DHS	2017	24.0
Sierra Leone	DHS	2013	89.6
Somalia	MICS	2006	98.0
Sudan (The)	MICS	2014	87.0
Togo	DHS	2013-2014	4.7
Uganda	DHS	2016	0.3
Tanzania, United Republic of	DHS	2015/2016	10.0
Yemen	DHS	2013	18.5

J. Unit costs for outpatient consultations and inpatient days

countryISO3	Outpatient Consultation	Inpatient Bed Day
BEN	\$ 3.06	\$ 14.33
BFA	\$ 2.75	\$ 12.22
CAF	\$ 2.41	\$ 9.18
CIV	\$ 4.06	\$ 21.64
CMR	\$ 4.27	\$ 22.57
DJI	\$ 4.12	\$ 22.37
EGY	\$ 23.55	\$ 175.53
ERI	\$ 1.32	\$ 4.49
ETH	\$ 4.65	\$ 19.02
GHA	\$ 12.19	\$ 59.00
GIN	\$ 3.22	\$ 13.76
GMB	\$ 7.92	\$ 42.30
GNB	\$ 3.15	\$ 14.16
IDN	\$ 10.62	\$ 70.27
IRQ	\$ 6.46	\$ 40.89
KEN	\$ 5.26	\$ 26.40
LBR	\$ 1.53	\$ 5.17
MLI	\$ 2.99	\$ 13.69
MRT	\$ 5.10	\$ 28.37
NER	\$ 1.46	\$ 5.14
NGA	\$ 7.71	\$ 41.90
SDN	\$ 22.77	\$ 126.42
SEN	\$ 3.54	\$ 17.79
SLE	\$ 4.84	\$ 20.52
SOM	\$ 2.41	\$ 9.18
TCD	\$ 2.62	\$ 12.61
TGO	\$ 2.04	\$ 8.23
TZA	\$ 4.74	\$ 21.68
UGA	\$ 4.06	\$ 17.93
YEM	\$ 12.19	\$ 67.52

Source: WHO CHOICE (https://www.who.int/choice/cost-effectiveness/inputs/country_inpatient_outpatient_2010.pdf)